Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	174.93	72.31	22.95	45.01	19.52
Short-Term Investments	558.59	183.86	147.36	166.86	321.59
Cash & Short-Term Investments	733.52	256.17	170.31	211.87	341.11
Cash Growth	186.35%	50.41%	-19.62%	-37.89%	-17.04%
Accounts Receivable	59.6	38.38	32.92	30.42	85.45
Inventory	9.13	14.11	23.97	13.29	27.33
Other Current Assets	30.02	22.9	10.23	8.01	10.86
Total Current Assets	832.27	331.56	237.43	263.6	464.75
Net Property, Plant & Equipment	-	-	25.06	27.49	32.6
Other Intangible Assets	225.44	266.65	299.61	342.46	376.69
Goodwill	101.54	105.25	103.37	105.67	105.67
Long-Term Investments	167.95	10.91	49.32	3	-
Other Long-Term Assets	233.44	227.41	72.43	20.45	317.87
Total Assets	1,561	941.77	787.22	762.67	1,298
Accounts Payable	3.24	5.23	2.43	5.31	8.4
Accrued Expenses	31.45	27.91	12.47	15.68	17.58
Current Portion of Long-Term Debt	-	-	-	76.7	-
Current Portion of Leases	1.1	1.27	0.41	0.72	1.41
Unearned Revenue	-	-	1.22	0.36	0.65
Other Current Liabilities	1.66	2.71	0.26	0.06	13.62
Total Current Liabilities	37.45	37.11	16.78	98.81	41.67
Long-Term Debt	446.19	-	-	-	320.72
Long-Term Leases	4.2	5.82	5.76	10.34	2.26
Other Long-Term Liabilities	55.58	68.41	63.77	56.04	111.79
Total Long-Term Liabilities	505.98	74.22	69.52	66.37	434.77
Total Liabilities	543.43	111.34	86.3	165.18	476.43
Preferred Stock	-	-	-	-	0.02
Common Stock	0.02	0.02	0.02	0.02	0.02
Additional Paid-in Capital	400.65	337.38	198.7	147.59	372.97
Accumulated Other Comprehensive Income	8.46	-5.94	-0.82	-0.98	-0.92
Retained Earnings	608.09	498.98	503.02	450.86	449.09
Total Common Shareholders' Equity	1,017	830.44	700.91	597.49	821.18
Shareholders' Equity	1,017	830.44	700.91	597.49	821.16
Total Liabilities & Equity	1,561	941.77	787.22	762.67	1,298
Total Debt	451.49	7.08	6.17	87.75	324.39
Net Cash (Debt)	282.03	249.08	164.14	124.12	16.72
Net Cash Growth	13.23%	51.75%	32.24%	642.28%	-
Net Cash Per Share	13.90	13.62	9.24	7.36	0.97
Book Value	1,017	830.44	700.91	597.49	821.18
Book Value Per Share	50.12	45.40	39.47	35.42	47.62
Tangible Book Value	690.23	458.54	297.94	149.36	338.81
Tangible Book Value Per Share	34.01	25.07	16.78	8.85	19.65

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q